Tag: Bitcoin

Shervin Pishevar: Touches With Twitter

If you did not catch the Twitter rampage earlier this year from Shervin Pishevar, here is a breakdown of the events. The tweets covered everything from the American bond market, the future of some stocks, and Silicon Valley. It was a lengthy Twitter splurge, which covered a lot of territory.

First, there is a little background to know about Pishevar. He has made many good investment moves, such as Uber, Dollar Shave Club, and Slack, so that is why he can comment on finances and the economy.

For some good news, Shervin Pishevar sees a shining light with some of the space programs, such as SpaceX. He also commented on the inspiring work coming from Virgin Hyperloop. By the way, he is a partner in the Virgin Hyperloop company.

Now for the other facts and figures he threw out there. He tweeted on a prediction that the stock market will take a complete drop of 6,000 points. He compared it to a bear waking up from a long winter’s hibernation. He has a theory that the decline is being caused by interest rates that continue to climb. Coupling the increasing rates with tax freebies, he believes the market will not be sustainable, and the crash is inevitable.

Bonds have lost their glimmer. Government bonds use to have some influence and help stabilize the economy. Central banks purchased bonds as a mechanism to offset the stock market. Pishevar tweets about how this form of manipulation is antiquated. He said it has worn out its welcome because it was used too many times.

Next he tackled the world markets. In his words, the US has exported inflation. By his accounts, this action has been taking place for years. The state of the US finances is not walled off from the rest of the world’s economy. Pishevar appears to have little hope that the current political climate will stop the exportation because of the international trade that is being tested and disrupted.

Shervin Pishevar speaks of the Silicon Valley as if it is crumbling like the pyramids. The Valley use to be as shiney as the bond market, but it too has burned itself out. The talent that use to beat the door down to get in is now looking elsewhere.

Shervin Pishevar Twitter inferno lasted for several hours, and it seemed like nothing was left untouched. Spectators wonder if that will be the last full rampage we hear from Shervin Pishevar until next year.

http://www.businessinsider.sg/shervin-pishevar-strange-21-hour-tweet-storm-2018-2/

Proteostasis is Issued a Negative Report by Sahm Adrangi

Kerrisdale Capital Management’s Sahm Adrangi has issued another negative report concerning a medication that is currently being developed. This time, the medication in question is Proteostasis Therapeutics’ new cystic fibrosis medication known as PTI-428. While it may have received the designations of Orphan Drug and Breakthrough Therapy by the Food and Drug Administration, Sahm Adrangi believes that the chances of the medication actually being effective for the medication are very unlikely.

When Proteostasis was granted these designations by the FDA, the company saw their stock price rise significantly but Kerrisdale Capital has taken a short position on the company. After researching the medication and company, he determined that they were not completely honest about the results or the drug’s effectiveness. He found that several key data points that showed negative outcomes of the Phase 2 trials were omitted in the releases to the public. This does not fare well for the drug or the patients that were hoping it would help to treat their difficult disease. Additionally, Sahm Adrangi believes that the small size of the placebo group in Phase 2 trials also contributed to the medication’s appearance of effectiveness. The negative instances in the small placebo group made the results of the therapy group appear to be much better than they actually were, especially with the omission of certain key details of the trial.

Sahm Adrangi is the Chief Investment Officer of Kerrisdale Capital Management as well as the founder. The company that was founded in 2009 with $1 million was managing around $150 million in capital in July 2017. Sahm Adrangi first earned recognition in the investing world after short-selling the stocks of Chinese companies that were operating fraudulently and trading in the United States. He and Kerrisdale Capital Management are well known for the published research about the companies that they have chosen to short. If Proteostasis’ new cystic fibrosis drug does fail during its Phase 3 trials, Sahm Adrangi and Kerrisdale Capital stand to make a good deal of money for their investors.

https://www.hvst.com/user/sahm-adrangi